#Switzerland #Basel #CordenPharma #Peptide Production

CordenPharma Expands Peptide Production with New Facility in Basel

CordenPharma has announced an ambitious expansion of its peptide manufacturing platform by establishing a state-of-the-art facility in Basel, Switzerland. This new investment, exceeding 500 million euros, is part of the company's broader strategy to enhance its production capabilities worldwide.

The decision to invest in Basel, a prominent biotech and pharmaceutical hub in Europe, has been strategically influenced by several factors. The location not only boasts an efficient infrastructure essential for peptide manufacturing but also offers optimal logistics with easy access to transportation networks. Additionally, the area is surrounded by established utilities capable of supporting large-scale chemical production.

One of the significant advantages of the Basel location is its access to a highly skilled workforce, thanks to its proximity to numerous renowned universities and research institutions. This ensures that CordenPharma can tap into a talent pool rich in expertise, which is crucial for maintaining quality and innovation in peptide manufacturing.

The new facility will focus on both small-scale and large-scale peptide production and will utilize advanced technologies, including state-of-the-art automation and digitalization. These enhancements aim to meet the stringent regulatory requirements and ensure the highest quality standards for products, including both injectable and oral peptide medications. With over 5,000 liters of peptide synthesizing reactors available, the capacity for various types of peptide projects, including GLP-1 peptides, is expected to significantly increase.

Construction of the facility will begin soon, with significant phases planned between 2025 and 2027, looking to commence commercial activities in the first half of 2028. This initiative is projected to create more than 300 new jobs, contributing to the local economy and fostering innovation in the region.

Simultaneously, CordenPharma is expanding its existing facility in Colorado, where it plans to significantly increase its peptide production capacity there as well. This expansion includes an additional 25,000 liters of peptide synthesizing capabilities, which will double the current capacity at that site.

Dr. Michael Quirmbach, CEO of CordenPharma Group, expressed enthusiasm about the new Swiss facility, highlighting its potential to provide flexible and efficient peptide manufacturing in line with the growing demand for innovative peptide-based therapeutics. The company aims to achieve sales exceeding 1 billion euros in its peptide platform by the year 2028, bolstering its position as a leading market player in the supply of integrated services ranging from active pharmaceutical ingredients (APIs) to final product delivery.

Judith Charpentier, co-director at Astorg, emphasized that CordenPharma's bold expansion reflects its commitment to meeting the rising demand for peptide manufacturing and enhancing access to life-saving medications. Astorg, the private equity firm that acquired CordenPharma in 2022, fully supports this growth initiative, which combines industrial excellence with strategic investment.

With these expansions, CordenPharma is well-positioned to solidify its leadership in the complex space of peptide contract development and manufacturing organizations (CDMO). The new facilities will significantly enhance the company's production capabilities, meeting both current and future needs in the peptide therapy market.

CordenPharma operates a global network of 11 facilities across Europe and North America. Its commitment to innovation and high-quality service has made it a trusted partner for biotechnology and pharmaceutical innovators seeking to advance their drug development lifecycle.

For more details on this significant development, visit CordenPharma's website.